Method | Sensitivity | Specificity | Prevalence | PPV | ||||
---|---|---|---|---|---|---|---|---|
TGLMM | 98.0 (96.7,99.3) | 87.5 (82.7,92.3) | 47.8 (37.9,57.7) | 87.8 (83.3,92.3) | ||||
Model 1 | 98.0 (96.7,99.3) | 87.4 (82.5, 92.3) | 49.3 (38.9,59.7) | 88.4 (84,92.7) | ||||
Model 2 | 98.1 (96.9,99.3) | 75.9 (69.3,82.5) | 47.8 (37.9,57.8) | 78.9 (71.9,85.9) | ||||
Model 3 | 91.7 (88.1,95.4) | 89 (85.4,92.7) | 47.8 (37.9,57.7) | 88.4 (84.1,92.7) | ||||
Intent-to-diagnose | 91.7 (88.1,95.3) | 76.2 (69.7,82.6) | 47.9 (37.9,57.9) | 78 (70.2,85.7) | ||||
Method | NPV | LR+ | LR − | AUC | ||||
TGLMM | 97.9 (96.4,99.5) | 7.8 (4.8,10.9) | 0.02 (0.01,0.04) | 0.99 (0.96,1) | ||||
Model 1 | 97.8 (96.1,99.4) | 7.8 (4.8,10.9) | 0.02 (0.01,0.04) | 0.99 (0.96,1) | ||||
Model 2 | 97.8 (96.2, 99.4) | 4.1 (2.9,5.2) | 0.02 (0.01,0.04) | 0.98 (0.97,1) | ||||
Model 3 | 92.1 (88.4,95.8) | 8.4 (5.5,11.3) | 0.09 (0.05,0.14) | 0.96 (0.93,0.99) | ||||
Intent-to-diagnose | 90.9 (86.4,95.5) | 3.8 (2.7,5.0) | 0.11 (0.06,0.16) | 0.93 (0.89,0.96) |